TY - JOUR
T1 - Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes
AU - Balasenthil, Seetharaman
AU - Liu, Suyu
AU - Dai, Jianliang
AU - Bamlet, William R.
AU - Petersen, Gloria
AU - Chari, Suresh T.
AU - Maitra, Anirban
AU - Chen, Nanyue
AU - Sen, Subrata
AU - McNeill Killary, Ann
N1 - Publisher Copyright:
© 2023
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Background and aims: While type 2 diabetes is a well-known risk factor for pancreatic ductal adenocarcinoma (PDAC), PDAC-induced new-onset diabetes (PDAC-NOD) is a manifestation of underlying PDAC. In this study, we sought to identify potential blood-based biomarkers for distinguishing PDAC-NOD from type 2 diabetes (T2DM) without PDAC. Materials and methods: By ELISA analysis, a migration signature biomarker panel comprising tissue factor pathway inhibitor (TFPI), tenascin C (TNC-FNIII-C) and CA 19–9 was analyzed in plasma samples from 50 PDAC-NOD and 50 T2DM controls. Results: Both TFPI (area under the curve (AUC) 0.71) and TNC-FNIII-C (AUC 0.69) outperformed CA 19–9 (AUC 0.60) in distinguishing all stages of PDAC-NOD from T2DM controls. The combined panel showed an AUC of 0.82 (95% CI = 0.73–0.90) (p = 0.002). In the PDAC-NOD early stage II samples, the three biomarkers had an AUC of 0.84 (95% CI = 0.73–0.93) vs CA 19-9, AUC = 0.60, (95% CI = 0.45–0.73), which also improved significance (p = 0.0123). Conclusion: The migration signature panel adds significantly to CA 19–9 to discriminate PDAC-NOD from T2DM controls and warrants further validation for high-risk group stratification.
AB - Background and aims: While type 2 diabetes is a well-known risk factor for pancreatic ductal adenocarcinoma (PDAC), PDAC-induced new-onset diabetes (PDAC-NOD) is a manifestation of underlying PDAC. In this study, we sought to identify potential blood-based biomarkers for distinguishing PDAC-NOD from type 2 diabetes (T2DM) without PDAC. Materials and methods: By ELISA analysis, a migration signature biomarker panel comprising tissue factor pathway inhibitor (TFPI), tenascin C (TNC-FNIII-C) and CA 19–9 was analyzed in plasma samples from 50 PDAC-NOD and 50 T2DM controls. Results: Both TFPI (area under the curve (AUC) 0.71) and TNC-FNIII-C (AUC 0.69) outperformed CA 19–9 (AUC 0.60) in distinguishing all stages of PDAC-NOD from T2DM controls. The combined panel showed an AUC of 0.82 (95% CI = 0.73–0.90) (p = 0.002). In the PDAC-NOD early stage II samples, the three biomarkers had an AUC of 0.84 (95% CI = 0.73–0.93) vs CA 19-9, AUC = 0.60, (95% CI = 0.45–0.73), which also improved significance (p = 0.0123). Conclusion: The migration signature panel adds significantly to CA 19–9 to discriminate PDAC-NOD from T2DM controls and warrants further validation for high-risk group stratification.
KW - Biomarkers
KW - Blinded Validation
KW - Diabetes
KW - Early Detection
KW - Pancreatic Cancer
UR - http://www.scopus.com/inward/record.url?scp=85173926935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173926935&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2023.117567
DO - 10.1016/j.cca.2023.117567
M3 - Article
C2 - 37774897
AN - SCOPUS:85173926935
SN - 0009-8981
VL - 551
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
M1 - 117567
ER -